Autolus Therapeutics To Present Clinical Data Update At The American College Of Rheumatology (ACR) Convergence 2025

2025-09-16 08:16:47

(MENAFN- GlobeNewsWire - Nasdaq) LONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025, in Chicago. Autolus will have a poster presentation, which will include updated follow up from the CARLYSLE study in patients with severe refractory systemic lupus erythematosus (srSLE).

Abstract: 2458
Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting autologous chimeric antigen receptor T-cell therapy (CAR T) with a fast off-rate binding domain, in patients with severe, refractory systemic lupus erythematosus (srSLE): preliminary results from the Phase I CARLYSLE study
Session date and time: Tuesday, October 28, 2025; 10:30am - 12:30pm Central Time
Presenting Author: Maria Leandro, MD

Summary: Initial findings from the ongoing CARLYSLE study of obe-cel in srSLE show a manageable safety profile, with no dose limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS) or Grade ≥2 cytokine release syndrome (CRS). SLEDAI-2K score reduction and clinical benefit were observed in all patients. In addition, three patients who had a complete renal response. Updated data will be presented at the conference.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit .

Contact:

Amanda Cray
+1 617-967-0207
...

MENAFN16092025004107003653ID1110068369

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.